Hopebridge Introduces Intuitive Patient Portal for Easier Access to Personalized Pediatric Care and Communications
January 17, 2024 08:00 ET
|
Hopebridge
INDIANAPOLIS, IN, Jan. 17, 2024 (GLOBE NEWSWIRE) -- To continue its vision of expanding access to quality, pediatric therapy and diagnostic services, Hopebridge recently launched a new patient...
Axial Therapeutics to Present at Upcoming Conferences
January 05, 2024 08:05 ET
|
Axial Therapeutics
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological...
Xolv Creates a New Venture to Embark on New Era of Innovation in Behavioral Health
January 03, 2024 16:53 ET
|
Xolv
WALNUT CREEK, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xolv, formerly Catalight’s IT and technology innovation group, proudly announces its transition to a new corporation today as part of a...
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
December 13, 2023 09:30 ET
|
NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
November 24, 2023 08:55 ET
|
SciSparc Ltd
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
November 21, 2023 13:41 ET
|
Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
November 20, 2023 08:05 ET
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Catalight Honored as a Healthy People 2030 Champion from Department of Health and Human Services
November 15, 2023 13:40 ET
|
Catalight
Walnut Creek, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Citing the company’s bold vision for the future, Catalight was recently named a Healthy People 2030 Champion by the Office of Disease...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
November 14, 2023 05:28 ET
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
November 06, 2023 12:00 ET
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...